Moleculin Biotech MBRX September 2024 Investor Presentation

Moleculin Biotech (NASDAQ: MBRX) is a clinical-stage biopharmaceutical company developing novel drug candidates including Annamycin, with ongoing collaboration with MD Anderson Cancer Center. The company has 200 years of combined drug development experience and 14 ongoing clinical trials, backed by an experienced management team led by CEO Walter V. Klemp.